ATE66374T1 - Zubereitungen und verfahren zur behandlung von blutungsstoerungen. - Google Patents
Zubereitungen und verfahren zur behandlung von blutungsstoerungen.Info
- Publication number
- ATE66374T1 ATE66374T1 AT86309197T AT86309197T ATE66374T1 AT E66374 T1 ATE66374 T1 AT E66374T1 AT 86309197 T AT86309197 T AT 86309197T AT 86309197 T AT86309197 T AT 86309197T AT E66374 T1 ATE66374 T1 AT E66374T1
- Authority
- AT
- Austria
- Prior art keywords
- treating
- preparations
- treatment
- methods
- bleeding disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/04—Materials for stopping bleeding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Surgery (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DK544685A DK544685D0 (da) | 1985-11-26 | 1985-11-26 | Terapeutisk komposition |
DK459286A DK459286D0 (da) | 1986-09-26 | 1986-09-26 | Terapeutisk komposition |
EP86309197A EP0225160B1 (de) | 1985-11-26 | 1986-11-25 | Zubereitungen und Verfahren zur Behandlung von Blutungsstörungen |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE66374T1 true ATE66374T1 (de) | 1991-09-15 |
Family
ID=26067544
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT86309197T ATE66374T1 (de) | 1985-11-26 | 1986-11-25 | Zubereitungen und verfahren zur behandlung von blutungsstoerungen. |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0225160B1 (de) |
JP (1) | JPH0780783B2 (de) |
AT (1) | ATE66374T1 (de) |
AU (1) | AU593042B2 (de) |
CA (1) | CA1281647C (de) |
ES (1) | ES2037664T3 (de) |
GR (1) | GR3002672T3 (de) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5472850A (en) * | 1991-04-10 | 1995-12-05 | Oklahoma Medical Research Foundation | Quantitative clotting assay for activated factor VII |
US5580560A (en) * | 1989-11-13 | 1996-12-03 | Novo Nordisk A/S | Modified factor VII/VIIa |
US5504064A (en) * | 1991-04-10 | 1996-04-02 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with an activator of FVII |
US5374617A (en) * | 1992-05-13 | 1994-12-20 | Oklahoma Medical Research Foundation | Treatment of bleeding with modified tissue factor in combination with FVIIa |
CZ83194A3 (en) * | 1991-10-11 | 1994-11-16 | Novo Nordisk As | Haemostatic preparation for inducing blood precipitation on a bleeding wound |
US5925738A (en) * | 1995-12-01 | 1999-07-20 | The American National Red Cross | Methods of production and use of liquid formulations of plasma proteins |
US20050032690A1 (en) * | 1997-09-10 | 2005-02-10 | Rojkjaer Lisa Payne | Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia |
US7033994B2 (en) | 1999-12-24 | 2006-04-25 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Medicinal compositions for preventing and treating hemorrhagic diseases associating thrombopathy |
US7015194B2 (en) | 2000-05-10 | 2006-03-21 | Novo Nordisk A/S | Pharmaceutical composition comprising factor VIIa and anti-TFPI |
BR0110659A (pt) * | 2000-05-10 | 2003-02-11 | Novo Nordisk As | Composição farmacêutica, kit, uso de um fator viia em combinação com um fator, xiii, e, métodos para intensificação da formação de coágulo de fibrina em um indivìduo e para tratar de episódios de hemorragia em um indivìduo |
JP2004537505A (ja) * | 2001-02-21 | 2004-12-16 | ザイモジェネティクス,インコーポレイティド | 血小板疾患を処理するための血液凝固第viii因子 |
PL369077A1 (en) * | 2001-07-20 | 2005-04-18 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides |
EP1446145A1 (de) | 2001-11-09 | 2004-08-18 | Novo Nordisk Health Care AG | Pharmaceutische zusammensetzung die faktor vii und tafi enthält |
US7125846B2 (en) | 2001-11-09 | 2006-10-24 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides |
US7291587B2 (en) | 2001-11-09 | 2007-11-06 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and TAFI polypeptides |
US7078479B2 (en) | 2001-11-09 | 2006-07-18 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and alpha2-antiplasmin polypeptides |
IL162239A0 (en) | 2001-12-21 | 2005-11-20 | Novo Nordisk Healthcare Ag | Liquid composition of factor vii polypeptides |
CN101675991A (zh) * | 2001-12-21 | 2010-03-24 | 诺和诺德医疗保健公司 | 因子ⅶ多肽的液体组合物 |
US20060233786A1 (en) * | 2002-05-23 | 2006-10-19 | Chugai Seiyaku Kabushiki Kaisha | Agent neutralizint tissue factor inhibitor and agent neutralizing activated blood coagulation factor viii preparation |
ES2523655T5 (es) | 2002-06-21 | 2018-04-23 | Novo Nordisk Health Care Ag | Composiciones sólidas estabilizadas de polipéptidos del Factor VIIa |
US7897734B2 (en) | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
RU2364609C2 (ru) | 2003-05-23 | 2009-08-20 | Ново Нордиск Хелт Кэр Аг | Стабилизация белка в растворе |
ATE547114T1 (de) | 2003-06-25 | 2012-03-15 | Novo Nordisk Healthcare Ag | Flüssige zusammensetzungen von factor vii polypeptiden |
CN102872451A (zh) | 2003-08-14 | 2013-01-16 | 诺和诺德医疗保健公司 | 因子vii多肽类的含水液体药物组合物 |
RU2373953C2 (ru) | 2003-12-19 | 2009-11-27 | Ново Нордиск Хелс Кеа Аг | Стабилизированная композиция, содержащая полипептид фактора vii |
US8461115B2 (en) | 2006-03-16 | 2013-06-11 | Stellaris Pharmaceuticals Aps | Methods for local treatment with factor VII |
WO2010149172A2 (en) * | 2009-06-24 | 2010-12-29 | Rigshospitalet | SYSTEMIC PRO-HEMOSTATIC EFFECT OF CLOTTING FACTORS IN COMBINATION WITH SYMPATHICOMIMETICS WITH AGONISTIC EFFECTS ON α-ADRENERGIC AND/OR β-ADRENERGIC RECEPTORS OF THE SYMPATHETIC NERVOUS SYSTEM, RELATED TO IMPROVED CLOT STRENGTH. |
EP2305289A1 (de) | 2009-09-16 | 2011-04-06 | Bio-Products & Bio-Engineering Aktiengesellschaft | Medizinische Produkte zur Behandlung von Blutgerinnungsstörungen |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4663164A (en) * | 1980-01-28 | 1987-05-05 | Baxter Travenol Laboratories, Inc. | Aqueous compositions for treating blood clotting factor inhibitors |
US4357321A (en) * | 1980-01-28 | 1982-11-02 | Baxter Travenol Laboratories, Inc. | Method and composition for treating clotting factor inhibitors |
JPH0686385B2 (ja) * | 1980-01-28 | 1994-11-02 | バクスタ−、インタ−ナショナル、インコ−ポレイテッド | 活性プロトロンビン複合体組成物およびその製造方法 |
US4382083A (en) * | 1981-06-25 | 1983-05-03 | Baxter Travenol Laboratories, Inc. | Therapeutic method for treating blood-clotting defects with factor VIIa |
US4479938A (en) * | 1981-06-25 | 1984-10-30 | Baxter Travenol Laboratories, Inc. | Therapeutic composition containing factor VIIa |
AU555305B2 (en) * | 1982-09-29 | 1986-09-18 | Bayer Corporation | Antihemophilic factor concentrate |
US4470969A (en) * | 1983-12-02 | 1984-09-11 | Miles Laboratories, Inc. | Process for producing a concentrate of coagulation factors VII and VIIa |
US4473553A (en) * | 1983-12-02 | 1984-09-25 | Miles Laboratories, Inc. | Process for producing a lipoprotein-poor concentrate of coagulation factors VII and VIIa |
GR860984B (en) * | 1985-04-17 | 1986-08-18 | Zymogenetics Inc | Expression of factor vii and ix activities in mammalian cells |
-
1986
- 1986-11-25 AU AU65670/86A patent/AU593042B2/en not_active Expired
- 1986-11-25 JP JP61278887A patent/JPH0780783B2/ja not_active Expired - Lifetime
- 1986-11-25 ES ES198686309197T patent/ES2037664T3/es not_active Expired - Lifetime
- 1986-11-25 EP EP86309197A patent/EP0225160B1/de not_active Expired - Lifetime
- 1986-11-25 CA CA000523778A patent/CA1281647C/en not_active Expired - Lifetime
- 1986-11-25 AT AT86309197T patent/ATE66374T1/de not_active IP Right Cessation
-
1991
- 1991-09-10 GR GR91401283T patent/GR3002672T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
EP0225160A2 (de) | 1987-06-10 |
EP0225160B1 (de) | 1991-08-21 |
ES2037664T3 (es) | 1993-07-01 |
JPH0780783B2 (ja) | 1995-08-30 |
AU6567086A (en) | 1987-05-28 |
GR3002672T3 (en) | 1993-01-25 |
JPS62195335A (ja) | 1987-08-28 |
EP0225160A3 (en) | 1988-03-30 |
AU593042B2 (en) | 1990-02-01 |
CA1281647C (en) | 1991-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE66374T1 (de) | Zubereitungen und verfahren zur behandlung von blutungsstoerungen. | |
ATE295176T1 (de) | Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen | |
DE69230112D1 (de) | Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin | |
ATE73331T1 (de) | Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus. | |
ATE71629T1 (de) | Methylenphosphonalkylphosphinate, pharmazeutische zubereitungen und verfahren zur behandlung abnormalen kalzium- und phosphat-stoffwechsels. | |
DE3483085D1 (de) | Desulfatohirudine, verfahren zu ihrer herstellung und pharmazeutische mittel. | |
DE3582439D1 (de) | Mittel zur behandlung von herzerkrankungen. | |
DE69132688T2 (de) | Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin | |
DE69829721D1 (de) | Verwendung von aktiviertem Protein-C zur Behandlung überschiessender Blutgerinnung bei Sepsis | |
HUP9903336A2 (hu) | Szulfonsav-N-[(amino-imino-metil)-fenil]-aza-heretero-ciklil-amid származékok és az ezeket tartalmazó gyógyszerkészítmények | |
UA45942A (uk) | 1,3-оксатіолан, його похідні, спосіб (варіанти) його одержання та фармацевтична композиція | |
ATE121100T1 (de) | Ein neues thrombomodulin ähnliches glykoprotein erhältlich aus harn. | |
DE3685853D1 (de) | Mittel zur behandlung von knochenkrankheiten. | |
ATE44156T1 (de) | Kovalent gebundener heparin-antithrombin iiikomplex, verfahren zu dessen herstellung und seine verwendung zur behandlung von thrombusembolie. | |
ATE120645T1 (de) | Verfahren und therapeutische zubereitungen für die behandlung von gerinnungsstörungen. | |
DE69527145T2 (de) | Verfahren zur behandlung von blutungsstorungen | |
ATE430578T1 (de) | Faktor viii oder von willebrand faktor zur behandlung von thrombopathie assoziierenden hämorrhagischen erkrankungen | |
ATE44750T1 (de) | Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats. | |
DK563886A (da) | Terapeutisk komposition | |
ATE69949T1 (de) | Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel. | |
ATE126437T1 (de) | Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf. | |
ATE70444T1 (de) | Topische methotrexatzubereitung zur behandlung hyperproliferativer epithelerkrankungen. | |
ATE128358T1 (de) | Therapeutische mittel für diabetisches gangrän. | |
ATE136776T1 (de) | Verwendung von heptastigmin zur behandlung der zerebralen ictus | |
ATE91236T1 (de) | Verwendung von follikelreifungshormon zur herstellung eines therapeutischen mittels zur behandlung von neoplasmen von gonadalem ursprung. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification | ||
EEIH | Change in the person of patent owner | ||
EELA | Cancelled due to lapse of time |